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problems with cognitive functions and problems with emotional dysregulation. 
ADHD was seen to impact everyday activities, social interactions and emotional 
functioning. These impacts had implications for the achievements at school; 
self-esteem and indulgence in risky behavior. Variables that moderate these 
impacts were also identified. The interrelationships among variables will be 
presented. The model was used to inform a strategy to evaluate outcomes of 
pharmacological treatments in adolescents with ADHD. The plausibility of the 
model was confirmed based on discussions with clinicians and drug 
development experts. CONCLUSIONS: An ADHD disease conceptual model was 
developed based on information from literature and stakeholders interviews, to 
describe ADHD in adolescents. It will be used to develop a strategy for PRO 
development in adolescent ADHD and identify new outcomes.  
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OBJECTIVES: To compare socio-demographic characteristics, comorbidities, 
health care resource use and work productivity assessments among adults 
diagnosed with attention-deficit/hyperactivity disorder (ADHD) from Europe (E) 
and the United States (US). METHODS: Data are from the 2011 National Health 
and Wellness Survey (NHWS), conducted online annually by Kantar Health 
among samples of adults obtained from international consumer panels. Data 
reported in this study were gathered September-December 2011 in Germany, UK, 
France, Spain, Italy, and the U.S. Comparisons of ADHD and non-ADHD control 
populations were presented previously. Those results are extended below, by 
comparing to differences between European and U.S. study participants, using 
chi-square tests of proportions. RESULTS: A total of 235 European and 676 US 
NHWS participants reported having received a diagnosis for ADHD from a health 
care professional. Diagnosed ADHD respondents were more frequently male 
(59% E vs. 56% US) and less likely married (38% E vs. 33% US) than non-ADHD 
controls. ADHD respondents were more likely to report sleep difficulties (67% E 
vs. 44% US; p<.05), anxiety (61% E vs. 58% US), depression (59% E vs. 60% US), or 
headaches (57% E vs. 63% US) than non-ADHD controls. Likelihoods of an 
emergency room visit (34% E vs. 24% US; p<0.05), or a hospitalization (32% E vs. 
12% US; p<0.05) within the past 6 months were greater among diagnosed ADHD 
respondents than non-ADHD controls. Diagnosed ADHD respondents were also 
more likely to report health-related work productivity loss (55% E vs. 34% US; 
p<0.05). CONCLUSIONS: Adults from Europe and the US reported high rates of 
comorbidity with various mental, emotional, or physical disorders, high rates of 
health resource utilization, and high rates of health-related work productivity 
loss, with many of these higher among European than US participants.  
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OBJECTIVES: Depression has a significant detrimental effect on HRQoL and 
functioning. The aim of this study was to assess HRQoL outcomes in randomized 
placebo-controlled studies of adult MDD patients receiving vortioxetine. 
METHODS: Effects on HRQoL and functioning were evaluated in adult MDD 
patients using the Short-Form 36 (SF-36), the Quality of Life Enjoyment and 
Satisfaction Scale-Short Form (Q-LES-Q-SF), the EuroQoL Five-Dimension (EQ-
5D), the Health Status Questionnaire (HSQ-12) and the Sheehan Disability Scale 
(SDS). Furthermore, HRQoL and functioning were assessed in a short-term study 
in elderly MDD patients (≥65 years). A random effects meta-analysis was 
performed on the short-term vortioxetine studies (n=4 for SF-36 and n=7 for 
SDS). Values are presented as change from baseline versus placebo. RESULTS: 
Adult patients were treated with placebo (n=1316) or vortioxetine (n=2155). The 
meta-analysis (FAS, MMRM) showed a statistically significant difference to 
placebo in favour of vortioxetine in the SF-36 Mental Component Summary 
(MCS) score (5mg: 2.6, p=0.001, n=604; 20mg: 4.8, p<0.001, n=328) and 4 domain 
scores (vitality, social functioning, role-emotional, and mental health). 
Standardised effect sizes showed the clinical relevance of these results. 
Improvement was significantly different from placebo in the EQ-5D Health State 
score for vortioxetine 10mg (7.5 points, p<0.05, n=86) (FAS, MMRM) and the Q-
LES-Q total score for vortioxetine 15mg (3.3 points, p<0.01, n=127) and 20mg (4.5 
points, p<0.0001, n=134) (FAS, LOCF). Improvement in functioning, measured 
with the SDS, was in favour of vortioxetine 10mg (-1.7, p=0.004, n=269) and 20mg 
(-2.4, p=0.006, n=234) (FAS, MMRM). In the elderly study, improvement in the 
HSQ-12 for vortioxetine 5mg (n=136) was significantly different from placebo 
(n=128) for Health Perception (10.4, p<0.0001), Mental Health (7.9, p<0.001), and 
Energy (6.4, p<0.05) domains (FAS, MMRM). CONCLUSIONS: Vortioxetine showed 
significant and meaningful improvements in HRQoL and functioning versus 
placebo across several MDD trials and relevant outcome instruments.  
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OBJECTIVES: This research presents an approximating model of global 
treatment satisfaction (GS) created using econometric techniques. GS questions 
are usually worded, “All things considered, how satisfied are you with the care 
you received…?” The economic interpretation of GS is higher satisfaction 
corresponds to higher utility. When thought of as utility, GS is tied to the 
assumptions of utility maximizing imbedded in consumer theory, and more 
specifically, to the concept of demand. Attempts in the literature to measure GS 
fall short because of lack of theoretical guidance and inconsistency in 
measurement and variable operationalization. We avoid these limitations by 
presenting a methodological approach that makes it possible to view GS from an 
economic perspective. METHODS: The model is based on data from an outcomes 
study of substance abuse treatment services; however, it can be used for any 
treatment population. The participants are 311 adults (average age 36.4) 
discharged from primary treatment (ASAM Level 1A) in 2006-2010. The model is 
based on a single ordinal five-item GS variable and two treatment-relevant 
covariates: post-treatment time abstinent from use (treatment outcome), and an 
adjustor variable indicating addiction severity. GS is treated as a latent variable. 
It is specified using ordered probit regression under the log-linear functional 
form. The structural part of the relation is isolated by setting the model error 
term to zero. RESULTS: The model estimate for the outcome variable is 0.205 
(S.E. 0.041; X2<0.0001), and for the severity variable 0.722 (S.E. 0.431; χ2 N.S). A set 
of GS indifference curves are presented based on severity and outcome 
equivalencies. CONCLUSIONS: The effort necessary to obtain higher GS 
increases on the margin. This is important given the strong relationship between 
addiction severity and treatment cost and given treatment resource constraints. 
This technique can be incorporated into the quality assurance activities in any 
health care setting.  
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OBJECTIVES: Prescribing of more than one antidepressant drug (poly-pharmacy) 
is not clinically substantiated in literature and such a practice could contribute 
to additional side-effects. Antidepressant drugs are prescribed to patients 
diagnosed with psychiatric and non-psychiatric medical conditions. The 
objective of this study was to determine the patient demographics, non-
demographic factors and physician characteristics associated with prescribing 
poly-pharmacy antidepressants in both psychiatric and non-psychiatric cases. 
METHODS: The 2000-2009 National Ambulatory Medical Care Survey database 
was accessed for medical records of patients who were prescribed the 
antidepressant drugs. The medical records were sorted into psychiatric and non-
psychiatric categories. A logistic regression analysis helped determine the 
patient demographic, non-demographic and physician characteristics associated 
with prescribing poly-pharmacy antidepressant drugs. RESULTS: For patients 
diagnosed with psychiatric illnesses: Patient demographic factors of age 
(p<0.0001), gender (p=0.0087), race/ethnicity (p=0.0091), method of payment 
(p=0.0283), non-demographic factors of diagnosis (p<0.0001), and number of 
medical condition diagnosed (p<0.0001, OR=1.259, CI=1.125-1.408) were 
significantly associated with prescribing poly-pharmacy antidepressant drugs. 
Among the physician related factors, physician specialty (p<0.0001) and the 
region of practice (South) (p=0.0475) were significantly associated with 
prescribing poly-pharmacy antidepressant drugs. For patients diagnosed with 
non-psychiatric illnesses: Patients’ age (p<0.0001), method of payment 
(p=0.0444), and among the non-demographic characteristics, the number of 
medical conditions diagnosed (p=0.0246, OR=1.16, CI=1.019-1.320), and patients 
diagnosed with circulatory system disease (p=0.0111) were significantly 
associated with the practice of poly-pharmacy. Of the physician related factors 
physicians classified as owners of non-solo practice (p=0.0306) were significantly 
associated with prescribing poly-pharmacy antidepressant drugs. 
CONCLUSIONS: The fact that more than 40% of poly-pharmacy antidepressant 
drugs was prescribed to patients diagnosed with non-psychiatric illnesses, and 
the significant association between the poly-pharmacy antidepressants 
prescribed and the number of medical conditions diagnosed in both psychiatric 
and non-psychiatric patients lends to further investigation as to the 
reasonableness of such practices.  
 
PMH58  
ATYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA IN BRAZIL: A DESCRIPTIVE 
ANALYSIS OF ACQUISITION COSTS  
Mosca M, Schneiders RE, Zimmermann IR, Alexandre RF, do Nascimento Jr JM,  
Gadelha CA 
Ministry of Health, Brasília, DF, Brazil  
OBJECTIVES: Several medicines are available in the Brazilian public health 
system (SUS) to treat schizophrenia. The Ministry of Health (MoH) and Brazilian 
states share the responsibility of acquiring the atypical antipsychotics, which 
have significant impact on the public budget. Here, we present the profile of 
financial resources allocated in the acquisition of atypical antipsychotics in the 
SUS. METHODS: Descriptive analysis of expenses with drugs, based on the 
amount dispensed and acquisition prices in 2011. Data were obtained from MoH 
databases. For quetiapine, olanzapine, risperidone and ziprasidone, we assumed 
the financial resources applied by both states and MoH; for clozapine, we needed 
to accounted only the MoH resources (current values of 2011; exchange rate: 
US$1 = R$2.04). RESULTS: In 2011, expenses with atypical antipsychotics 
(clozapine, quetiapine, olanzapine, risperidone, and ziprasidone) for 
